Drug discovery and development success rates have not improved over the last 15-20 years, and by some measures, especially those for New Chemical Entities (NCEs), the success rates are declining. NCE success rates through preclinical testing are around 50%, and from Phase 1 to FDA approval they are around 6%. This puts overall NCE success rates from preclinical to FDA approval at around 3%! This webinar will briefly review current data on pipeline success rates and then discuss the three highest causes for NCEs attrition and potential innovations that can improve NCEs survival, leading to more effective and efficient drug discovery and development.